Data are needed on minimal factor activity (FA) levels required to prevent bleeding in
hemophilia. We aimed to evaluate associations between hemophilia type and FA level and …

Joint health is a key contributor to quality of life in patients with hemophilia. However,
variables that impact long-term joint outcomes have not been comprehensively defined. A …

Haemorrhagic manifestations in patients with haemophilia A and B are considered quite
similar for comparable level of factor deficiency. We investigated the bleeding frequency and …

Introduction The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB)
is not well known. Aim We evaluated joint health in Nordic patients in relation to their …

Introduction Joint arthropathy is the long‐term consequence of joint bleeding in people with
severe haemophilia. Aim This study assessed change in joint health over time in subjects …

To quantify variation in clinical phenotype of severe haemophilia we performed a single
centre cohort study among 171 severe haemophilia patients. Age at first joint bleed …

Objective. Arthropathy is the major cause of morbidity in haemophilia. In an attempt to
establish optimal therapeutic regimens for persons with haemophilia, we hypothesized that …

Hemophilia A (HA) and hemophilia B (HB) are X‐linked, recessive disorders. Although their
clinical manifestations are essentially indistinguishable, it has been suggested that bleeding …

Essentials• High‐quality data are lacking on use of prophylaxis in adults with hemophilia
and arthropathy.• SPINART was a 3‐year randomized clinical trial of late/tertiary prophylaxis …

A cohort study was performed among 214 patients with severe haemophilia, born 1944–
1994, to describe changes in treatment over the last 3 decades and its effects on clotting …